Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024

2024-01-02

临床结果

GAITHERSBURG, Md., Jan. 02, 2024 (GLOBE NEWSWIRE) --Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced an abstract on pemvidutide in subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease1 will be presented at the NASH-TAG Conference, which will be held in Park City, UT on January 4-6, 2024. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH2. Details for the presentation are as follows: Title: Pemvidutide-Induced Liver Fat Reduction in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease Correlates with Improvements in Non-Invasive Markers of Inflammation and Fibrosis: Results of a 24-week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (abstract #51) Authors: Stephen A. Harrison, Shaheen Tomah, John J. Suschak, Jonathan Kasper, M. Scot Roberts, M. Scott Harris, Sarah K. Browne Date: Saturday, January 6, 2024 A copy of the abstract will be accessible on the Events section of the Altimmune website. 1previously termed Non-Alcoholic Fatty Liver Disease 2 previously termed NASH About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and MASH, formerly known as NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit . Follow @Altimmune, Inc. on LinkedIn Follow @AltimmuneInc on Twitter Investor Contact: Rich Eisenstadt Chief Financial Officer Phone: 240-654-1450 reisenstadt@altimmune.com Media Contact: Danielle Cantey Evoke Canale Phone: 619-826-4657 danielle.cantey@evokegroup.com

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构